This phase II trial studies how well trametinib works in treating patients with juvenile
myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment
(refractory). Trametinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
I. To determine the objective response rate to trametinib in children with recurrent or
refractory juvenile myelomonocytic leukemia (JMML).
I. To further define and describe the toxicities of single agent trametinib in children with
recurrent or refractory JMML.
II. To further characterize the pharmacokinetics of trametinib in children with recurrent or
III. To prospectively evaluate mutant allele burden as a marker of disease activity in JMML.
IV. To measure the rate of complete responses in children with recurrent or refractory JMML.
V. To measure the duration of response among responders.
I. To describe the distribution of JMML diagnostic criteria in children with recurrent or
Patients receive trametinib orally (PO) once daily (QD) on days 1-28. Treatment repeats every
28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up annually for up to 5 years.
von Recklinghausen's Disease,
Juvenile Myelomonocytic Leukemia,
NF1 Gene Mutation,
Activating RAS Mutation,
PTPN11 Gene Mutation,
Blasts Under 20 Percent of Bone Marrow Nucleated Cells,
Blasts Under 20 Percent of Peripheral Blood White Cells
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.